TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference

Rhea-AI Summary

WALTHAM, Mass., Sept. 02, 2021 – TScan Therapeutics (Nasdaq: TCRX) announced that its CEO, David Southwell, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 4:15 p.m. ET. A live webcast of the event will be accessible on the company’s website, with an archived replay available post-event.

TScan Therapeutics focuses on developing T-cell receptor engineered therapies for cancer treatment, including TSC-100 and TSC-101 for hematologic malignancies.

WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19^th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.

A live webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website following the event.

About TScan Therapeutics, Inc.

TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Contacts

Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com

Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com

FAQ

When will David Southwell speak at the Morgan Stanley Conference for TCRX?

David Southwell will speak on September 10, 2021, at 4:15 p.m. ET.

Where can I watch the TCRX fireside chat live?

The live webcast can be viewed on TScan Therapeutics' 'Events and Presentations' page on their website.

What therapies is TScan Therapeutics developing?

TScan is developing TCR engineered T cell therapies, including TSC-100 and TSC-101 for treating hematologic malignancies.

What type of company is TScan Therapeutics (TCRX)?

TScan Therapeutics is a biopharmaceutical company focused on T-cell receptor engineered therapies for cancer.